Mah and Pitre published this systematic review and meta-analysis in BMC Complementary Medicine and Therapies in 2021, pooling data from three randomized controlled trials that compared oral magnesium supplementation to placebo specifically in older adults with insomnia.

The pooled results showed that magnesium supplementation reduced sleep onset latency (the time it takes to fall asleep) by about 17 minutes compared to placebo. The Insomnia Severity Index scores also improved in the magnesium groups, though the evidence quality was rated as low overall due to the small number of trials.

While 17 minutes faster sleep onset may seem modest, for people with insomnia who routinely lie awake for 45-60 minutes or more, this represents a meaningful improvement. The meta-analysis noted that the effect appeared stronger in people who were magnesium-deficient at baseline, suggesting the supplement works best when correcting an underlying nutritional gap.

Abbasi and colleagues published this randomized, double-blind, placebo-controlled trial in the Journal of Research in Medical Sciences in 2012. They enrolled 46 elderly subjects (aged 60-75) with insomnia and randomly assigned them to receive either 500 mg of magnesium or placebo daily for 8 weeks.

The magnesium group showed significant improvements in multiple sleep measures: sleep time increased, sleep efficiency improved, time to fall asleep decreased, and early morning awakening was reduced. Blood tests revealed that magnesium supplementation increased serum melatonin (the sleep hormone) and decreased serum cortisol (the stress hormone) - providing a biological mechanism for the sleep improvement.

This is one of the most frequently cited studies supporting magnesium for sleep because it measured both subjective sleep quality and objective biological markers. The changes in melatonin and cortisol suggest that magnesium affects the hormonal pathways that regulate the sleep-wake cycle, not just subjective perception.

A randomized, double-blind, placebo-controlled trial published in Frontiers in Nutrition in 2024 tested magnesium L-threonate (a form designed to cross the blood-brain barrier more effectively) in adults with self-reported sleep problems.

Participants receiving magnesium L-threonate showed significant improvements in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), as well as improvements in daytime functioning compared to the placebo group. The form of magnesium used is notable because L-threonate has been shown in animal studies to increase magnesium levels in the brain more effectively than other forms.

This study is important because it used a form of magnesium specifically designed for brain effects, addressing the criticism that standard magnesium supplements may not reach the brain in sufficient quantities. The positive results suggest that when magnesium is delivered in a brain-available form, sleep benefits are more reliably achieved.

A randomized, double-blind, placebo-controlled trial published in Nutrients in 2025 tested magnesium bisglycinate (also called magnesium glycinate, a highly bioavailable form) in healthy adults over 8 weeks.

The magnesium bisglycinate group showed significant improvements in self-reported sleep quality compared to the placebo group. The study is notable for testing magnesium in healthy adults rather than only in people with diagnosed insomnia or magnesium deficiency, suggesting that even people without clinical sleep disorders may benefit from supplementation.

Magnesium bisglycinate is one of the most popular forms of magnesium supplement because glycine - the amino acid attached to the magnesium - also has calming and sleep-promoting properties. The combination may provide additive sleep benefits beyond magnesium alone.

A review published in Nutrients in 2025 examined the biological mechanisms through which magnesium affects sleep regulation. The review synthesized evidence from both human and animal studies to explain why magnesium supplementation could improve sleep.

Magnesium activates GABA-A receptors in the brain - the same receptors targeted by prescription sleep medications like benzodiazepines and the "Z-drugs" (zolpidem/Ambien). By enhancing GABA activity, magnesium increases inhibitory signaling in the brain, promoting relaxation and reducing the neural arousal that keeps people awake.

Magnesium also regulates the production and release of melatonin (the hormone that signals the body it is time to sleep), reduces cortisol (the stress hormone that promotes wakefulness), and relaxes skeletal muscles (reducing restless legs and muscle tension that can interfere with sleep). These multiple pathways provide a strong biological rationale for why magnesium supplementation could improve sleep quality.

An analysis of the CARDIA (Coronary Artery Risk Development in Young Adults) study published in Sleep Health in 2022 examined the relationship between magnesium intake and sleep outcomes in a large prospective cohort. The CARDIA study has followed participants since 1985-86, providing long-term data on diet and health.

Higher magnesium intake was significantly associated with longer sleep duration and better self-reported sleep quality. The association remained significant after adjusting for age, sex, race, education, physical activity, total calorie intake, caffeine, alcohol, and other dietary factors.

While observational studies cannot prove causation, the CARDIA study''s large sample size, long follow-up, and comprehensive adjustment for confounding factors strengthen the case that the association between magnesium and sleep is real rather than a coincidence. People who consume more magnesium - whether from diet or supplements - appear to sleep better.

A systematic review published in Nutrients in 2024 examined the effects of supplemental magnesium on both anxiety and sleep quality across available randomized controlled trials. The review assessed the balance of evidence for magnesium as a sleep aid.

The review concluded that given the generally positive results across studies, the strong biological rationale from preclinical research, and the minimal side effect profile, supplemental magnesium is "likely useful" in the treatment of mild insomnia. The benefit appeared strongest in people with low magnesium status at baseline - suggesting that the supplement works best when correcting an actual deficiency.

This is clinically relevant because magnesium deficiency is common. Surveys suggest that roughly 50% of Americans do not meet the recommended daily intake of magnesium, and blood tests underestimate deficiency because most magnesium is stored inside cells, not in the blood. Many people with sleep problems may have unrecognized low magnesium status that supplementation could correct.

A randomized, double-blind, placebo-controlled trial published in BMC Nutrition in 2025 tested magnesium L-threonate (marketed as Magtein) for effects on both sleep quality and cognitive performance in adults.

Participants receiving magnesium L-threonate showed improvements in sleep quality measures and also demonstrated better cognitive performance on tests conducted the following day. This finding is important because it shows the sleep improvement is not just a subjective perception - it translates into measurably better daytime brain function.

Poor sleep is one of the most common causes of daytime cognitive impairment, affecting memory, attention, and decision-making. If magnesium supplementation improves sleep sufficiently to enhance next-day cognitive performance, it provides a functional benefit that goes beyond simply feeling more rested.

Rawji and colleagues published a systematic review in Current Nutrition Reports in 2022 identifying 5 randomized controlled interventional studies that examined magnesium supplementation and sleep outcomes. The review evaluated study quality and summarized findings across the available trials.

Three of the five studies reported that magnesium supplementation improved at least one measure of sleep quality compared to placebo. The positive results were concentrated in studies that enrolled participants with existing sleep problems rather than healthy sleepers, and in studies with longer supplementation periods (8 weeks rather than shorter).

The review noted that while the overall direction of evidence favors a benefit, the small number of available trials, small sample sizes, and heterogeneous study designs limit the strength of conclusions. The authors called for larger, well-designed trials to confirm the findings, particularly in people with documented magnesium deficiency and insomnia.

Magnesium supplementation has a well-established safety profile. The most common side effects at high doses are mild gastrointestinal effects including loose stools and diarrhea, which resolve when the dose is reduced. Serious adverse effects are extremely rare in people with normal kidney function.

This safety profile contrasts favorably with prescription sleep medications. Benzodiazepines and Z-drugs (zolpidem, zaleplon) carry risks of physical dependency, withdrawal symptoms, cognitive impairment, daytime drowsiness, falls (particularly dangerous in elderly people), and complex sleep behaviors. Long-term use of these medications is generally discouraged.

Even if magnesium''s sleep benefits are modest, the minimal risk makes the risk-benefit calculation favorable. A supplement that provides even small sleep improvements with virtually no side effects is potentially more valuable for long-term use than a drug that provides larger improvements but with significant risks. For mild insomnia in particular, magnesium may be a reasonable first-line approach before considering pharmaceutical options.